risperidone has been researched along with hp 873 in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Bordeau, KJ; Chiang, Y; Conway, PG; Corbett, R; Glamkowski, EJ; Hartman, HB; Helsley, GC; Strupczewski, JT; Szewczak, MR; Wilmot, CA | 1 |
| Cai, J; Hartman, HB; Kerman, LL; Kongsamut, S; Roehr, JE; Sandrasagra, A; Tang, L; Weissensee, P | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Conway, PG; Corbett, R; Cornfeldt, M; Rush, DK; Strupczewski, JT; Szewczak, MR; Wilmot, CA | 1 |
| Conway, PC; Corbett, R; Dunn, RW; Hartman, H; Helsley, GC; Kerman, LL; Strupczewski, JT; Woods, AT | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Kumar, R; Sachdev, PS | 1 |
| Conley, RR; Fijal, BA; Hoffmann, VP; Houston, JP; Kinon, BJ; Stauffer, VL; Witte, MM; Zhao, F | 1 |
| Citrome, L; Hochfeld, M; Meng, X; Stahl, SM | 1 |
| Knoepflmacher, D; Shapley, L; Turner, EH | 1 |
| Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
5 review(s) available for risperidone and hp 873
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
4 trial(s) available for risperidone and hp 873
| Article | Year |
|---|---|
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.
Topics: Adult; Antipsychotic Agents; Apoptosis Regulatory Proteins; Benzodiazepines; Biomarkers, Pharmacological; Black or African American; Drug Resistance; Genotype; Humans; Isoxazoles; Membrane Proteins; Membrane Transport Proteins; Olanzapine; Piperidines; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, AMPA; Risperidone; Schizophrenia; White People | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2012 |
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
7 other study(ies) available for risperidone and hp 873
| Article | Year |
|---|---|
3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Dopamine Antagonists; In Vitro Techniques; Isoxazoles; Male; Piperidines; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 1995 |
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; CHO Cells; Cricetinae; Humans; Isoxazoles; Kinetics; Piperidines; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4; Receptors, Dopamine D5; Receptors, Serotonin | 1996 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Clozapine; Dopamine Antagonists; Haloperidol; Isoxazoles; Male; Mice; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Risperidone; Saimiri; Serotonin Antagonists | 1995 |
Effects of atypical antipsychotic agents on social behavior in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Catalepsy; Chlorpromazine; Clozapine; Diazepam; Haloperidol; Isoxazoles; Male; Mice; Mice, Inbred Strains; Piperidines; Raclopride; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Salicylamides; Social Behavior | 1993 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Databases, Factual; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Publication Bias; Pyrimidines; Quetiapine Fumarate; Quinolones; Risperidone; United States; United States Food and Drug Administration | 2012 |